Headlines about Interpace Diagnostics Group (NASDAQ:IDXG) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the business services provider an impact score of 45.5806982653737 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern’s rankings:

Separately, Maxim Group initiated coverage on Interpace Diagnostics Group in a report on Tuesday, August 15th. They set a “buy” rating and a $5.00 target price for the company.

Shares of Interpace Diagnostics Group (IDXG) opened at 1.36 on Friday. The stock’s market cap is $30.14 million. The firm’s 50-day moving average price is $1.06 and its 200-day moving average price is $1.82. Interpace Diagnostics Group has a 12-month low of $0.70 and a 12-month high of $19.80.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings data on Thursday, August 10th. The business services provider reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $3.86 million for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/interpace-diagnostics-group-idxg-earning-somewhat-favorable-press-coverage-accern-reports/1538001.html.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.